Legis Daily

Interagency Patent Coordination and Improvement Act of 2025

USA119th CongressHR-4570| House 
| Updated: 7/21/2025
Joe Neguse

Joe Neguse

Democratic Representative

Colorado

Judiciary Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
This bill establishes an Interagency Task Force on Patents between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). Congress recognizes that USPTO patent examiners can benefit from additional information housed at other federal agencies, particularly for assessing prior art and ensuring consistency in patent applications related to human drugs and biological products . The task force's core purpose is to coordinate efforts, improve communication, and ensure effective implementation of activities concerning these patents. Comprised of employees from both agencies with relevant expertise, the task force will facilitate reciprocal access to information. Its key activities include sharing general process information, data on new patent and product approvals, new technologies, prior art, and scientific trends. A crucial function involves establishing a process for the FDA to provide the USPTO with information regarding drug and biological product approvals, including public availability dates and, when necessary, access to non-public application and labeling information for patent examiners. Additionally, the USPTO will assist the FDA in its ministerial role of listing patents. The bill mandates the task force to establish robust protocols to safeguard the confidentiality of shared information. These protocols require a 30-day notice to product sponsors before information is shared and mandate that the USPTO keep confidential data separate from pending patent applications. Within four years of enactment, the USPTO Director must report to Congress on the task force's effectiveness, identifying useful information types and recommending future interagency coordination opportunities.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 118-1717
Interagency Patent Coordination and Improvement Act of 2023
Apr 10, 2025

Latest Companion Bill Action

S 119-1097
Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
Jul 21, 2025
Introduced in House
Jul 21, 2025
Referred to the House Committee on the Judiciary.
  • Bill from Previous Congress

    HR 118-1717
    Interagency Patent Coordination and Improvement Act of 2023


  • April 10, 2025

    Latest Companion Bill Action

    S 119-1097
    Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.


  • July 21, 2025
    Introduced in House


  • July 21, 2025
    Referred to the House Committee on the Judiciary.

Commerce

Related Bills

  • S 119-1097: Interagency Patent Coordination and Improvement Act of 2025

Interagency Patent Coordination and Improvement Act of 2025

USA119th CongressHR-4570| House 
| Updated: 7/21/2025
This bill establishes an Interagency Task Force on Patents between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). Congress recognizes that USPTO patent examiners can benefit from additional information housed at other federal agencies, particularly for assessing prior art and ensuring consistency in patent applications related to human drugs and biological products . The task force's core purpose is to coordinate efforts, improve communication, and ensure effective implementation of activities concerning these patents. Comprised of employees from both agencies with relevant expertise, the task force will facilitate reciprocal access to information. Its key activities include sharing general process information, data on new patent and product approvals, new technologies, prior art, and scientific trends. A crucial function involves establishing a process for the FDA to provide the USPTO with information regarding drug and biological product approvals, including public availability dates and, when necessary, access to non-public application and labeling information for patent examiners. Additionally, the USPTO will assist the FDA in its ministerial role of listing patents. The bill mandates the task force to establish robust protocols to safeguard the confidentiality of shared information. These protocols require a 30-day notice to product sponsors before information is shared and mandate that the USPTO keep confidential data separate from pending patent applications. Within four years of enactment, the USPTO Director must report to Congress on the task force's effectiveness, identifying useful information types and recommending future interagency coordination opportunities.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 118-1717
Interagency Patent Coordination and Improvement Act of 2023
Apr 10, 2025

Latest Companion Bill Action

S 119-1097
Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
Jul 21, 2025
Introduced in House
Jul 21, 2025
Referred to the House Committee on the Judiciary.
  • Bill from Previous Congress

    HR 118-1717
    Interagency Patent Coordination and Improvement Act of 2023


  • April 10, 2025

    Latest Companion Bill Action

    S 119-1097
    Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.


  • July 21, 2025
    Introduced in House


  • July 21, 2025
    Referred to the House Committee on the Judiciary.
Joe Neguse

Joe Neguse

Democratic Representative

Colorado

Judiciary Committee

Commerce

Related Bills

  • S 119-1097: Interagency Patent Coordination and Improvement Act of 2025
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted